Edition:
United States

Beigene Ltd (BGNE.OQ)

BGNE.OQ on NASDAQ Stock Exchange Global Select Market

128.34USD
23 May 2019
Change (% chg)

-- (--)
Prev Close
$128.34
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
98,012
52-wk High
$220.09
52-wk Low
$105.19

Latest Key Developments (Source: Significant Developments)

Beigene Posts Qtrly Net Loss Attributable Of $167.6 Million
Thursday, 9 May 2019 07:19pm EDT 

May 10 (Reuters) - Beigene Ltd <6160.HK>::QTRLY NET LOSS ATTRIBUTABLE TO BEIGENE, LTD. $167.6 MILLION VERSUS LOSS OF $104.6 MILLION.QTRLY TOTAL REVENUES $77.8 MILLION VERSUS $32.5 MILLION.  Full Article

BeiGene Q1 Loss Per Share $0.22
Thursday, 9 May 2019 04:06pm EDT 

May 9 (Reuters) - Beigene Ltd <6160.HK>::BEIGENE REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.22.COLLABORATION REVENUE TOTALED $20.41 MILLION FOR Q1 ENDED MARCH 31, 2019, COMPARED TO $9.29 MILLION FOR SAME PERIOD IN 2018.QTRLY LOSS PER SHARE $0.22.  Full Article

Beigene Ltd Says CEO's Total Compensation For FY 2018 Was $27.9 Mln Versus $10.3 Mln In FY 2017
Monday, 29 Apr 2019 06:34am EDT 

April 29 (Reuters) - Beigene Ltd <6160.HK>::BEIGENE LTD SAYS CEO JOHN V. OYLER'S TOTAL COMPENSATION FOR FY 2018 WAS $27.9 MILLION VERSUS $10.3 MILLION IN FY 2017- SEC FILING.BEIGENE LTD SAYS GENERAL MANAGER OF CHINA AND PRESIDENT XIAOBIN WU'S TOTAL COMPENSATION FOR FY 2018 WAS $21.5 MILLION.BEIGENE LTD - RATIO OF 2018 ANNUAL TOTAL COMPENSATION OF CEO TO MEDIAN OF ANNUAL TOTAL COMPENSATION OF ALL EMPLOYEES IS 135:1.  Full Article

Bioatla And Beigene Form Worldwide Collaboration To Develop And Commercialize Novel Conditionally Active Biologic Ctla-4 Therapy
Tuesday, 9 Apr 2019 06:05am EDT 

April 9 (Reuters) - Beigene Ltd <6160.HK>::BIOATLA AND BEIGENE FORM WORLDWIDE COLLABORATION TO DEVELOP AND COMMERCIALIZE NOVEL CONDITIONALLY ACTIVE BIOLOGIC CTLA-4 THERAPY.BIOATLA LLC - WILL RECEIVE AN UPFRONT PAYMENT OF $20 MILLION AND A MILESTONE PAYMENT UPON REACHING DEFINED EARLY CLINICAL OBJECTIVES.BIOATLA - BEIGENE WILL HOLD A CO-EXCLUSIVE LICENSE WITH BIOATLA TO DEVELOP AND MANUFACTURE PRODUCT CANDIDATE GLOBALLY.BIOATLA - IS ALSO ELIGIBLE TO RECEIVE UP TO $249 MILLION IN MILESTONE PAYMENTS.  Full Article

Beigene Reports Qtrly Loss Per Share Of $0.35
Wednesday, 27 Feb 2019 04:15pm EST 

Feb 27 (Reuters) - Beigene Ltd <6160.HK>::BEIGENE REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS.BEIGENE LTD QTRLY NET LOSS PER ADS ATTRIBUTABLE TO BEIGENE LTD $4.52.BEIGENE LTD QTRLY LOSS PER SHARE $0.35.BEIGENE LTD QTRLY TOTAL REVENUES $58.67 MILLION VERSUS $18.17 MILLION.  Full Article

Hillhouse Capital Management Ltd Reports 1.7 Pct Stake In Beigene Ltd
Thursday, 3 Jan 2019 04:49pm EST 

Jan 3 (Reuters) - Beigene Ltd <6160.HK>::HILLHOUSE CAPITAL MANAGEMENT, LTD. REPORTS 1.7 PERCENT STAKE IN BEIGENE LTD AS OF JANUARY 1 - SEC FILING.HILLHOUSE CAPITAL MANAGEMENT, LTD. PREVIOUSLY REPORTED 9.29 PERCENT STAKE IN BEIGENE LTD AS OF FEBRUARY 8, 2016.  Full Article

Zymeworks, Beigene Announce License And Collaboration Agreement For Zymeworks' Her2-Targeted Therapeutic Candidates
Tuesday, 27 Nov 2018 06:30am EST 

Nov 27 (Reuters) - Beigene Ltd <6160.HK>::ZYMEWORKS AND BEIGENE ANNOUNCE LICENSE AND COLLABORATION AGREEMENT FOR ZYMEWORKS’ HER2-TARGETED THERAPEUTIC CANDIDATES, ZW25 AND ZW49, IN ASIA-PACIFIC AND RESEARCH AND LICENSE AGREEMENT FOR ZYMEWORKS’ AZYMETRIC™ AND EFECT™ PLATFORMS GLOBALLY.ZYMEWORKS INC - ZYMEWORKS WILL RECEIVE TOTAL UPFRONT PAYMENTS OF US$40 MILLION UNDER ZW25 AND ZW49 AGREEMENTS AND US$20 MILLION UNDER PLATFORM AGREEMENT.ZYMEWORKS INC - BEIGENE ACQUIRES EXCLUSIVE DEVELOPMENT AND COMMERCIAL RIGHTS TO ZYMEWORKS' BISPECIFIC CANDIDATES, ZW25 AND ZW49, IN ASIA.ZYMEWORKS INC - BEIGENE ALSO ACQUIRES LICENSES FOR ZYMEWORKS' AZYMETRIC AND EFECT PLATFORMS.ZYMEWORKS INC - BEIGENE ACQUIRES EXCLUSIVE RIGHTS TO ZW25 AND ZW49, IN ASIA (EXCLUDING JAPAN), AUSTRALIA, AND NEW ZEALAND.ZYMEWORKS INC - ZYMEWORKS ELIGIBLE TO RECEIVE DEVELOPMENT AND COMMERCIAL MILESTONE PAYMENTS PLUS POTENTIAL ROYALTIES ON PRODUCT SALES..ZYMEWORKS - IS ELIGIBLE TO RECEIVE UP TO US$390 MILLION IN DEVELOPMENT AND COMMERCIAL MILESTONE PAYMENTS FOR BOTH PRODUCT CANDIDATES.ZYMEWORKS - UNDER TERMS OF AGREEMENT FOR AZYMETRIC AND EFECT PLATFORMS, CO ELIGIBLE TO RECEIVE UP TO AN AGGREGATE OF US$702 MILLION IN MILESTONE PAYMENTS.ZYMEWORKS - ELIGIBLE TO GET UPTO $702 MILLION IN DEVELOPMENT & COMMERCIAL MILESTONE PAYMENTS FOR UP TO 3 BISPECIFIC PRODUCT CANDIDATES DEVELOPED.  Full Article

Beigene Reports Quarterly Total Revenues Of $54.2 Million
Wednesday, 7 Nov 2018 05:06pm EST 

Nov 8 (Reuters) - Beigene Ltd <6160.HK>::QTRLY TOTAL REVENUES $54.2 MILLION VERSUS $220.2 MILLION.QTRLY NET LOSS ATTRIBUTABLE WAS $144 MILLION VERSUS PROFIT OF $117.4 MILLION.  Full Article

Beigene Initiates Global Head-To-Head Phase 3 Clinical Trial Of Zanubrutinib
Wednesday, 7 Nov 2018 05:06pm EST 

Nov 8 (Reuters) - Beigene Ltd <6160.HK>::BEIGENE INITIATES GLOBAL HEAD-TO-HEAD PHASE 3 CLINICAL TRIAL OF ZANUBRUTINIB.  Full Article

Beigene Announces Updated Results From Phase 1 Clinical Trial Of Zanubrutinib
Friday, 12 Oct 2018 06:00am EDT 

Oct 12 (Reuters) - Beigene Ltd <6160.HK>::BEIGENE ANNOUNCES UPDATED RESULTS FROM PHASE 1 CLINICAL TRIAL OF ZANUBRUTINIB IN PATIENTS WITH WALDENSTRÖM’S MACROGLOBULINEMIA.BEIGENE LTD - FIRST U.S. NDA FILING FOR ZANUBRUTINIB EXPECTED TO FILE IN FIRST HALF OF 2019.BEIGENE LTD - TREATMENT WITH ZANUBRUTINIB WAS GENERALLY WELL-TOLERATED & MAJORITY OF ADVERSE EVENTS WERE GRADE 1 OR 2 IN SEVERITY.BEIGENE LTD - UPDATED RESULTS FROM STUDY INCLUDED THAT OVERALL RESPONSE RATE WAS 92 PERCENT.BEIGENE LTD - 4 PATIENTS DISCONTINUED STUDY TREATMENT DUE TO DISEASE PROGRESSION & 1 PATIENT REMAINS ON TREATMENT POST-DISEASE PROGRESSION.BEIGENE - UPDATED STUDY RESULTS INCLUDED NINE PATIENTS DISCONTINUED DUE TO AES.  Full Article